EDX Medical Group PLC
24 August 2026
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
24 August 2026
AIM: EDX
("EDX Medical" or "the Company")
Equity Fundraising of £2.7 million
CAMBRIDGE, UK: EDX Medical Group plc, which develops and supplies innovative digital diagnostic products and services to improve the early detection and treatment of major diseases, announces that it has raised approximately £2.7m through a subscription for 19,378,563 new ordinary shares of 1p each in the Company (the "Subscription Shares") at a price of 14p per share (the "Fundraising"). Each Subscription Share subscribed for entitles the subscriber to warrants over 2 ordinary shares in the capital of the Company ("the Warrants") at an exercise price of 3p per Warrant, exercisable from 20 July 2028 to 19 July 2029.
The net proceeds of the Fundraising will be used to support the expansion of the Company's new employee health screening service. This service comprises a package of comprehensive biomarker testing panels, general health and family history checks. The service also offers a bespoke follow-up service which includes the provision of highly accurate advanced diagnostic tests if required.
The Company is pleased to report that discussions with respect to definitive contracts are progressing well in relation to the agreements in principle to provide the health screening service to three significant UK employers previously announced on 15 July 2026. Testing is still expected to commence in the last quarter of 2026. Two further large companies have now approached EDX Medical to explore the provision of this new health screening service and discussions are ongoing. The Board remain very excited by the size of commercial opportunity that these discussions represent.
The Company announced in April 2026 that it expected to record revenue for the year ended 31 March 2026 of £1.2 million - the quantum that the Company had invoiced for the provision of diagnostic tests during the financial year. The Company has received the bulk of the invoiced revenues but as processing of these orders ran beyond the end of the financial year, the Board - following discussion with the Company's auditors - have deferred recognition of £860,000 revenue into the current financial year.
Application has been made for the Subscription Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will occur on 28 August 2026.
Professor Sir Chris Evans, OBE, founder of EDX Medical, commented: "Investors in the Company have again demonstrated their confidence in the Company's strategy to provide class-leading diagnostic tests and fully support the expansion of our employee health screening programme where employers and employees can both reap the benefits of highly accurate tests which assess risks across a very wide range of health conditions and illnesses."
Total Voting Rights
In accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, the Company hereby announces that following the Fundraising, it will have 431,373,146 Ordinary Shares in issue, each share carrying the right to one vote.
The above figure of 431,373,146 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
The directors of EDX Medical accept responsibility for the contents of this announcement.
For enquiries, please contact:
|
EDX Medical Group plc |
|
|
Dr Mike Hudson (Chief Executive Officer) |
+44 (0)7812 345 301 |
|
Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
|
Stuart Andrews |
+44 (0) 20 7523 8318 |
|
Media House International |
|
|
Ramsay Smith Gary McQueen |
+44 (0)7788 414856 + 44 (0)7834 694609 |
|
IFC Advisory (Investor Relations) |
|
|
Graham Herring Tim Metcalfe |
+44 (0) 203 934 6630 |
About EDX Medical Group plc
The EDX Medical Group plc is listed on the AIM market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.
EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.